Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes
Open Access
- 2 July 2024
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 213, 111764
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Boehringer Ingelheim Corp USA
- Canadian Institutes of Health Research
This publication has 54 references indexed in Scilit:
- Ketones: the double-edged sword of SGLT2 inhibitors?Diabetologia, 2022
- Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinJACC, 2022
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trialDiabetologia, 2021
- Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and DiabetesKidney International Reports, 2021
- Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension2021
- The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?Kidney International, 2020
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 DiabetesJACC: Heart Failure, 2020
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney diseaseDiabetologia, 2019
- Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 DiabetesJACC, 2017
- Alteration of microvascular permeability in acute kidney injuryMicrovascular Research, 2009